methyl-(2,4,6-trimethyl-benzyl)-ether | 5336-55-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl-(2,4,6-trimethyl-benzyl)-ether
• 英文别名: Methyl-(2,4,6-trimethyl-benzyl)-aether；2.4.6-Trimethyl-1-methoxymethyl-benzol；2-(Methoxymethyl)-1,3,5-trimethylbenzene
• CAS: 5336-55-0
• 化学式: C₁₁H₁₆O
• 分子量: 164.247
• InChiKey: DZAMPSPWYDTXLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  异丁腈 、 methyl-(2,4,6-trimethyl-benzyl)-ether 在 三氯化铁 作用下， 反应 12.0h， 以76%的产率得到N-(2,4,6-Trimethyl-benzyl)-isobutyramide
  参考文献：
  名称：

  A NEW METHOD FOR THE SYNTHESIS OFN-BENZYLAMIDES

  摘要：

  Benzyl amides are obtained from benzyl chlorides with excellent yields in mild conditions by using hydrated ferric chloride, FeCl3.6H2O, as Lewis acid catalyst and common nitriles as both solvents and reagents.

  DOI：

  10.1081/scc-120006004
• 作为产物：
  描述：

  2,4,6-三甲基氯苄 在 氢氧化钾 作用下， 生成 methyl-(2,4,6-trimethyl-benzyl)-ether
  参考文献：
  名称：

  Nauta; Dienske, Recueil des Travaux Chimiques des Pays-Bas, 1936, vol. 55, p. 1000,1003

  摘要：

  DOI：

文献信息

• Simple, High Yield Preparation of<i>N</i>-Benzylacetamides by Lewis Acid-Catalyseed Reaction of Benzyl Chlorides or Benzyl Methyl Ethers with Acetonitrile
  作者：Mesut Kacan、Alexander McKillop

  DOI：10.1080/00397919308018613

  日期：1993.8

  Abstract Reaction of either benzyl chlorides or benzyl methyl ethers with hydrated ferric chloride in acetonitrile results in smooth Ritter reaction and formation of N-benzylacetamides in excellent yield.

  摘要 苄基氯或苄基甲基醚与水合氯化铁在乙腈中的反应会导致平稳的 Ritter 反应并以优异的产率形成 N-苄基乙酰胺。
• A NOVEL CLEAVAGE WITH NITRIC ACID OF POLYMETHYLATED DIBENZYL SELENIDES AND SELENOXIDES
  作者：Hitomi Suzuki、Kazumasa Ohnishi

  DOI：10.1246/cl.1981.111

  日期：1981.1.5

  When treated with nitric acid at low temperature, the title selenides and selenoxides undergo a novel cleavage reaction to give the corresponding benzyl nitrates and elemental selenium.

  在低温下用硝酸处理时，标题中的硒化物和硒氧化物会发生一种新颖的裂解反应，生成相应的苄基硝酸盐和元素硒。
• HYDROXIDE-CATALYZED FORMATION OF SILICON-OXYGEN BONDS BY DEHYDROGENATIVE COUPLING OF HYDROSILANES AND ALCOHOLS
  申请人：CALIFORNIA INSTITUTE OF TECHNOLOGY

  公开号：US20170029447A1

  公开（公告）日：2017-02-02

  The present disclosure is directed to methods for dehydrogenatively coupled hydrosilanes and alcohols, the methods comprising contacting an organic substrate having at least one organic alcohol moiety with a mixture of at least one hydrosilane and sodium and/or potassium hydroxide, the contacting resulting in the formation of a dehydrogenatively coupled silyl ether. The disclosure further described associated compositions and methods of using the formed products.

  本公开涉及一种将脱氢偶联的氢硅烷和醇的方法，所述方法包括将至少具有一个有机醇基团的有机底物与至少一种氢硅烷和氢氧化钠和/或氢氧化钾的混合物接触，所述接触导致形成脱氢偶联的硅醚。该公开还描述了相关的组合物和使用所形成产品的方法。
• HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES
  申请人：——

  公开号：US20030236416A1

  公开（公告）日：2003-12-25

  Compounds having therapeutic utility are of formula (I) B—X—(CH 2 ) n —CR 2 R 3 —CR 4 R 5 —COY  (I) wherein n = 0 - 1; X is S(O) 0-2 , Y is OR 1 or NHOH; R 2 and R 4 are independently H or a group (optionally substituted with R 10 ) selected from C 1-6 alkyl, C 2-6 alkenyl, aryl, C 1-6 alkyl-aryl, heteroaryl, C 1-6 alkyl-heteroaryl, heterocycloalkyl, C 1-6 alkyl-heterocycloalkyl, cycloalkyl and C 1-6 alkyl-cycloalkyl; and R 1 , R 3 and R 5 are independently H or C 1-6 alkyl; provided that not more than two of R 2 , R 3 , R 4 and R 5 are H; or any of CR 2 R 3 , CR 4 R 5 and CR 2 —CR 4 is a cycloalkyl or heterocycloalkyl ring optionally substituted with R 10 or a group (optionally substituted with R 10 ) selected from C 1-6 alkyl, aryl, C 1-6 alkyl-aryl, heteroaryl and C 1-6 alkyl-heteroaryl; B is heterocycloalkyl (optionally substituted by R 6 or R 7 ) bonded through carbon to X, or C 1-6 alkyl-heterocycloalkyl (optionally substituted with R 6 or R 7 ), or a group (substituted with R 6 ) selected from C 1-8 alkyl, C 2-6 alkenyl and C 2-6 alkynyl; R 6 is N(R 7 ) 2 , OR 7 , COR 7 , C(=NOR 9 )R 7 , NR 7 R 8 , S(O) 0-2 R 9 or SO 2 N(R 7 ) 2 ; R 7 is H or a group selected from C 1-6 alkyl, aryl, C 1-6 alkyl-aryl, heteroaryl, C 1-6 alkyl-heteroaryl, cycloalkyl, C 1-6 alkyl-cycloalkyl, heterocycloalkyl and C 1-6 alkyl-heterocycloalkyl, wherein said group is optionally substituted with R 9 , COR 9 , SO 0-2 R 9 , CO 2 R 9 , OR 9 , CONR 1 R 9 , NR 1 R 9 , halogen, CN, SO 2 NR 1 R 9 or NO 2 , and for each case of N(R 7 ) 2 the R 7 groups are the same or different or N(R 7 ) 2 is heterocycloalkyl optionally substituted with R 9 , COR 9 , SO 0-2 R 9 , CO 2 R 9 , OR 9 , CONR 1 R 9 , NR 1 R 9 , halogen, CN, SO 2 NR 1 R 9 or NO 2 ; R 8 is COR 7 , CON(R 7 ) 2 , CO 2 R 9 or SO 2 R 9 ; R 9 is C 1-6 alkyl, aryl, C 1-6 alkyl-aryl, heteroaryl or C 1-6 alkyl-heteroaryl; and R 10 is OR 7 , COR 7 , CO 2 R 1 , CON(R 7 ) 2 , NR 7 R 8 , S(O) 0-2 R 9 , SO 2 N(R 7 ) 2 , CN, halogen or cycloimidyl (optionally substituted with R 1 ); and the salts, solvates, hydrates, N-oxides, protected amino, protected carboxy and protected hydroxamic acid derivatives thereof.

  具有治疗效用的化合物的公式为(I)B—X—(CH2)n—CR2R3—CR4R5—COY  (I)，其中n为0-1；X为S(O)0-2，Y为OR1或NHOH；R2和R4独立地为H或从C1-6烷基、C2-6烯基、芳基、C1-6烷基芳基、杂芳基、C1-6烷基杂芳基、杂环烷基、C1-6烷基杂环烷基、环烷基和C1-6烷基环烷基中选择的（可选地用R10取代的）基团；R1、R3和R5独立地为H或C1-6烷基；但不得超过两个R2、R3、R4和R5为H；或CR2R3、CR4R5和CR2—CR4中的任何一个为杂环烷基或杂环烷基环，可选地用R10取代，或从C1-6烷基、芳基、C1-6烷基芳基、杂芳基和C1-6烷基杂芳基中选择的（可选地用R10取代的）基团；B为通过碳与X相连的杂环烷基（可选地用R6或R7取代），或C1-6烷基杂环烷基（可选地用R6或R7取代），或从C1-8烷基、C2-6烯基和C2-6炔基中选择的（用R6取代的）基团；R6为N(R7)2、OR7、COR7、C(=NOR9)R7、NR7R8、S(O)0-2R9或SO2N(R7)2；R7为H或从C1-6烷基、芳基、C1-6烷基芳基、杂芳基、C1-6烷基杂芳基、环烷基、C1-6烷基环烷基、杂环烷基和C1-6烷基杂环烷基中选择的基团，其中所述基团可选地用R9、COR9、SO0-2R9、CO2R9、OR9、CONR1R9、NR1R9、卤素、CN、SO2NR1R9或NO2取代，对于每种情况的N(R7)2，R7基团相同或不同，或N(R7)2为可选地用R9、COR9、SO0-2R9、CO2R9、OR9、CONR1R9、NR1R9、卤素、CN、SO2NR1R9或NO2取代的杂环烷基；R8为COR7、CON(R7)2、CO2R9或SO2R9；R9为C1-6烷基、芳基、C1-6烷基芳基、杂芳基或C1-6烷基杂芳基；R10为OR7、COR7、CO2R1、CON(R7)2、NR7R8、S(O)0-2R9、SO2N(R7)2、CN、卤素或环亚咪唑基（可选地用R1取代）；及其盐、溶剂化合物、水合物、N-氧化物、保护氨基、保护羧基和保护羟胺衍生物。
• THERAPEUTIC COMPOUNDS
  申请人：Old David W.

  公开号：US20080015231A1

  公开（公告）日：2008-01-17

  A compound having a formula is disclosed herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.

  本文披露了一种具有化学式的化合物。还披露了与之相关的治疗方法、组合物和药物。